Literature DB >> 6478363

Phenylketonuria and its variants: observations on intellectual functioning.

C Netley, W B Hanley, H L Rudner.   

Abstract

The age at diagnosis, dietary treatment and intelligence quotient (IQ) of 119 patients with phenylketonuria (PKU) and its variants who were under long-term observation were studied. In 27 of the 79 patients with classic PKU the diagnosis had been made and treatment begun late (after 2 months of age). The mean IQ of these 27 patients was 57.6 when they were in their early 20s (although 2 had normal IQs). In contrast, among the 52 patients with classic PKU who were not treated late the mean IQ was 93.6 for the 27 who were still receiving dietary therapy. The mean IQs were 99.3 and 92.7 at ages 5 (when the diet was discontinued) and 15 years respectively for the 12 who had been treated "adequately". It was 76.0 for the 13 who were "over-treated" (malnourished) in the first 6 months of life. Among the patients with atypical PKU, who were treated early, the mean IQs were 110.0 for the 7 who were still receiving dietary therapy and 102.7 for the 12 who were not. The 21 patients with persistent benign hyperphenylalaninemia, who were not treated, had a mean IQ of 104.2. The most important factor in the ultimate IQ of patients with classic PKU is very early diagnosis (by 2 weeks of age) along with immediate initiation of dietary therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6478363      PMCID: PMC1483577     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  16 in total

1.  Phenylketonuria due to a deficiency of dihydropteridine reductase.

Authors:  S Kaufman; N A Holtzman; S Milstien; L J Butler; A Krumholz
Journal:  N Engl J Med       Date:  1975-10-16       Impact factor: 91.245

2.  NEWBORN PHENYLKETONURIA DETECTION PROGRAM IN MASSACHUSETTS.

Authors:  R A MACCREADY; M G HUSSEY
Journal:  Am J Public Health Nations Health       Date:  1964-12

3.  Phenylalaninaemia. Differential diagnosis.

Authors:  M E Blaskovics; G E Schaeffler; S Hack
Journal:  Arch Dis Child       Date:  1974-11       Impact factor: 3.791

4.  The efficacy of dietary therapy for phenylketonuria.

Authors:  W B Hanley; L S Linsao; C Netley
Journal:  Can Med Assoc J       Date:  1971-06-19       Impact factor: 8.262

5.  Malnutrition with early treatment of phenylketonuria.

Authors:  W B Hanley; L Linsao; W Davidson; C A Moes
Journal:  Pediatr Res       Date:  1970-07       Impact factor: 3.756

6.  Atypical phenylketonuria. An approach to diagnosis and management.

Authors:  J S Yu; S J Stuckey; M T O'Halloran
Journal:  Arch Dis Child       Date:  1970-08       Impact factor: 3.791

7.  Effect of undernutrition in early life on physical and mental development.

Authors:  V Cabak; R Najdanvic
Journal:  Arch Dis Child       Date:  1965-10       Impact factor: 3.791

8.  The early treatment of phenylketonuria.

Authors:  J L Kennedy; W Wertelecki; L Gates; B P Sperry; V M Cass
Journal:  Am J Dis Child       Date:  1967-01

9.  A third allele at the phenylalanine-hydroxylase locus in mild phenylketonuria (hyperphenylalaninaemia).

Authors:  L I Woolf; B L Goodwin; W I Cranston; D N Wade; F Woolf; F P Hudson; M S McBean
Journal:  Lancet       Date:  1968-01-20       Impact factor: 79.321

10.  Admissions of phenylketonuric patients to residential institutions before and after screening programs of the newborn infant.

Authors:  R A MacCready
Journal:  J Pediatr       Date:  1974-09       Impact factor: 4.406

View more
  2 in total

1.  Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury.

Authors:  M Dennis; L Lockyer; A L Lazenby; R E Donnelly; M Wilkinson; W Schoonheyt
Journal:  J Autism Dev Disord       Date:  1999-02

2.  Cognitive function in untreated subjects with mild hyperphenylalaninemia: a systematic review.

Authors:  Noushin Rostampour; Rojin Chegini; Silva Hovsepian; Farzaneh Zamaneh; Mahin Hashemipour
Journal:  Neurol Sci       Date:  2022-06-21       Impact factor: 3.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.